Here’s Why GE HealthCare Stock Sank in April

• The tariff conflict between the U.S. and China hurts GE HealthCare’s earnings.

• Hospital capital equipment spending in China continues to be sluggish.

• An improvement in the trade conflict will create upside potential for GE HealthCare, and management believes China is a long-term growth opportunity.

Shares in medical equipment company GE HealthCare Technologies (NASDAQ: GEHC) declined by 12.9% in April, according to data provided by S&P Global Market Intelligence. The key reason for the decline comes from the “Liberation Day” tariffs announced by President Donald Trump at the start of the month.

The tariffs and the subsequent response, notably from China, have a significant impact on a company that’s a large exporter to the country and uses components sourced from China in its products. Management previously estimated (based on the pre-April tariff announcements) a negative impact of $0.05 in earnings per share (EPS) in 2025 from tariffs. Still, the new tariffs announced in April are expected to have an incremental negative impact of $0.80 in 2025, for a total of $0.85.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Consequently, on its first-quarter earnings call in late April, management lowered its earnings and cash-flow expectations for 2025:

• Full-year organic revenue growth is still expected in the 2%-3% range.

• Adjusted EPS is now expected to be in the $3.90-$4.10 range, compared with prior guidance of $4.61-$4.75.

• Free cash flow is now expected to be at least $1.2 billion compared to prior guidance of at least $1.75 billion.

CEO Peter Arduini discussed tariffs on the earnings call. He said, “We have conservatively assumed that the bilateral U.S. and China tariffs continue, accounting for 75% of our total net tariff impact.” As such, the U.S./China trade tariff conflict is the key relationship to watch for GE HealthCare investors.

It’s a somewhat frustrating situation for investors because the company’s investment case rests on the idea that solid underlying but low growth in developed markets would be supplemented by higher growth in end markets like China, where there’s a desire to improve healthcare standards.

Management sees China as an attractive long-term market, but tariffs aside, there are near-term headwinds. For example, management lowered guidance last year on lower demand from China, as the hospital capital equipment spending has taken far longer to drop into orders than management expected.